Glenmark Pharmaceuticals Ltd
NSE :GLENMARK BSE :532296 Sector : PharmaceuticalsBuy, Sell or Hold GLENMARK? Ask The Analyst
BSE
prev close
OPEN PRICE
bid price (qty)
offer price (qty)
volume
Today's low / high
52 WK low / high
NSE
prev close
open price
bid price (qty)
offer price (qty)
volume
Today's' low / high
52 WK low / high
13 Nov 1539.40 (-2.39%) | 12 Nov 1577.05 (-3.50%) | 11 Nov 1634.20 (-1.94%) | 08 Nov 1666.50 (0.55%) | 07 Nov 1657.35 (-6.31%) | 06 Nov 1768.95 (2.54%) | 05 Nov 1725.15 (1.52%) | 04 Nov 1699.25 (0.53%) | 01 Nov 1690.30 (-0.25%) | 31 Oct 1694.55 (1.47%) | 30 Oct 1670.00 (-0.30%) | 29 Oct 1675.10 (-2.24%) | 28 Oct 1713.50 (2.99%) | 25 Oct 1663.80 (-0.64%) | 24 Oct 1674.55 (-0.67%) | 23 Oct 1685.90 (0.22%) | 22 Oct 1682.25 (-2.01%) | 21 Oct 1716.80 (-1.25%) | 18 Oct 1738.45 (0.18%) | 17 Oct 1735.30 (-2.59%) | 16 Oct 1781.45 (-1.30%) |
Price Chart Historical Data Technical Chart
Technical Analysis
Short Term Investors
Very Bearish
Medium Term Investors
Very Bearish
Long Term Investors
Bullish
Moving Averages
5 DMA
Bearish
1614.73
10 DMA
Bearish
1665.19
20 DMA
Bearish
1680.28
50 DMA
Bearish
1700.19
100 DMA
Bearish
1578.9
200 DMA
Bullish
1293.01
Intraday Support and Resistance
(Based on Pivot Points) |
Updated On Nov 13, 2024 04:00 PM For Next Trading Session
Pivots | Classic | Fibonacci | Camarilla | Woodie | DM |
---|---|---|---|---|---|
R3 | 1626.81 | 1602.13 | 1554.81 | - | - |
R2 | 1602.13 | 1580.72 | 1549.68 | 1600.46 | - |
R1 | 1570.76 | 1567.49 | 1544.54 | 1567.42 | 1586.45 |
P | 1546.08 | 1546.08 | 1546.08 | 1544.41 | 1553.93 |
S1 | 1514.71 | 1524.67 | 1534.26 | 1511.37 | 1530.4 |
S2 | 1490.03 | 1511.44 | 1529.12 | 1488.36 | - |
S3 | 1458.66 | 1490.03 | 1523.99 | - | - |
Key Metrics
EPS
57.32
P/E
26.84
P/B
1.89
Dividend Yield
0.16%
Market Cap
43,440 Cr.
Face Value
1
Book Value
814.02
ROE
-50.87%
EBITDA Growth
618.71 Cr.
Debt/Equity
0.34
Shareholding History
Quarterly Result (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Quaterly Results
Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
INCOME | 3055.79 | 3327.81 | 2670.88 | 3860.49 | 3275.68 |
PROFIT | 182.37 | 68.79 | -393.41 | -2285.2 | 340.27 |
EPS | 5.31 | -2.9 | -12.45 | -43.17 | 12.06 |
Glenmark Pharmaceuticals Ltd Quaterly Results
Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
INCOME | 2193.75 | 2306.99 | 1623.91 | 8081.41 | 2385.19 |
PROFIT | 293.58 | 317.62 | 4.87 | 841.36 | 453.73 |
EPS | 9.63 | 10.72 | -0.72 | 163.5 | 16.08 |
Profit & Loss (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 6943.01 | 7721.83 | 9576.39 | 9032.11 | 10299.46 | 10705.37 | 11227.94 | 12482.71 | 12579.76 | 13246.04 | |
PROFIT | 263.52 | 743.05 | 1155.03 | 805.34 | 818.68 | 755.72 | 941.32 | 1107.67 | 609.68 | -4473.72 | |
EPS | 7.3 | 26.33 | 39.29 | 28.49 | 32.78 | 27.5 | 34.38 | 35.21 | 13.37 | -50.8 |
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 5358.49 | 6306 | 8220.99 | 5709.21 | 6787.67 | 7289.2 | 8032.82 | 9202.67 | 9237.97 | 14232.55 | |
PROFIT | 1139.79 | 1484.9 | 2322 | 1016.26 | 1344.95 | 1340.12 | 1589.58 | 1643.77 | 1578.33 | 1425.03 | |
EPS | 36.72 | 52.6 | 75.86 | 35.95 | 57.49 | 48 | 58.46 | 70.8 | 42.84 | 183.11 |
Balance Sheet (Figures in Rs. Crores)
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 |
Reserves Total | 7,819.71 | 9,445.71 | 9,058.43 | 7,036.41 | 6,042.29 | 5,576.97 | 5,135.26 | 4,464.31 | 3,601.42 | 1,756.36 |
Total Shareholders Funds | 7,847.93 | 9,473.93 | 9,086.65 | 7,064.63 | 6,070.51 | 5,605.19 | 5,163.48 | 4,492.53 | 3,629.64 | 1,783.49 |
Minority Interest | -0.38 | 365.34 | 351.47 | -0.35 | -0.39 | -0.38 | -0.37 | -0.42 | -0.3 | -0.19 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 |
Unsecured Loans | 1,230.93 | 4,607.88 | 3,962.02 | 4,985.72 | 4,868.63 | 4,442.56 | 4,619.64 | 4,721.06 | 3,972.58 | 3,763.24 |
Total Debt | 1,230.93 | 4,607.88 | 3,962.02 | 4,985.72 | 4,868.63 | 4,448.67 | 4,639.38 | 4,723.65 | 3,988.11 | 3,799.93 |
Other Liabilities | 540.52 | 397.59 | 152.5 | 196.68 | 429.27 | 89.14 | 2.6 | 32.74 | 76.99 | 121.92 |
Total Liabilities | 9,619 | 14,844.74 | 13,552.64 | 12,246.68 | 11,368.02 | 10,142.62 | 9,805.09 | 9,248.5 | 7,694.44 | 5,705.15 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 9,619.64 | 10,359.59 | 10,213.47 | 8,731.58 | 8,269.83 | 6,527.27 | 5,367.95 | 4,769.92 | 4,300.54 | 3,495.47 |
Less: Accumulated Depreciation | 5,409.48 | 4,937.83 | 4,326.23 | 3,602.73 | 3,241.28 | 2,857.01 | 2,338.4 | 2,014.83 | 1,706.99 | 1,480.09 |
Net Block | 4,210.16 | 5,421.76 | 5,887.24 | 5,128.85 | 5,028.55 | 3,670.26 | 3,029.55 | 2,755.09 | 2,593.55 | 2,015.38 |
Capital Work in Progress | 661.88 | 1,189.64 | 1,009.87 | 1,381.67 | 1,221.89 | 1,398.94 | 1,121.87 | 708.11 | 542.8 | 477.13 |
Investments | 789.66 | 44.57 | 49.62 | 24.63 | 24.59 | 29.66 | 14.66 | 15.69 | 17.2 | 17.12 |
Inventories | 2,513.05 | 2,373.62 | 2,499.83 | 2,276.83 | 2,135.62 | 2,252.07 | 2,030.59 | 2,139.05 | 1,567.76 | 1,269.04 |
Sundry Debtors | 1,858.41 | 3,665.17 | 3,101.14 | 2,572.06 | 2,408.96 | 2,194.59 | 2,331.81 | 2,404.32 | 2,492.65 | 2,511.77 |
Cash and Bank Balance | 1,659.46 | 1,160.3 | 1,411.52 | 1,139.16 | 1,111.24 | 937.77 | 1,234.69 | 1,057.66 | 857.12 | 775.88 |
Loans and Advances | 1,397.17 | 3,526.44 | 1,269.87 | 1,371.54 | 1,147.78 | 1,312.4 | 1,391.61 | 1,273.61 | 986.77 | 774.38 |
Total Current Assets | 7,428.08 | 10,725.53 | 8,282.35 | 7,359.58 | 6,803.61 | 6,696.83 | 6,988.69 | 6,874.64 | 5,904.3 | 5,331.07 |
Current Liabilities | 3,807.27 | 3,935.93 | 2,914.64 | 2,763.7 | 2,744.43 | 2,662.08 | 2,357.82 | 2,252.41 | 2,364.42 | 2,334.38 |
Provisions | 932.08 | 590.51 | 584.5 | 564.45 | 555.91 | 484.11 | 432.46 | 262.95 | 134.03 | 216.78 |
Total Current Liabilities & Provisions | 4,739.35 | 4,526.44 | 3,499.14 | 3,328.16 | 3,300.34 | 3,146.18 | 2,790.28 | 2,515.36 | 2,498.44 | 2,551.16 |
Net Current Assets | 2,688.74 | 6,199.09 | 4,783.21 | 4,031.42 | 3,503.27 | 3,550.65 | 4,198.41 | 4,359.27 | 3,405.86 | 2,779.91 |
Deferred Tax Assets | 1,049.72 | 1,805.91 | 1,969.55 | 1,852.18 | 1,770.85 | 1,761.63 | 1,728.58 | 1,553.35 | 1,274.96 | 169.73 |
Deferred Tax Liability | 0.28 | 0.51 | 314.93 | 346.26 | 331.59 | 378.68 | 408.32 | 242.08 | 210.07 | 222.52 |
Net Deferred Tax | 1,049.44 | 1,805.4 | 1,654.62 | 1,505.92 | 1,439.26 | 1,382.95 | 1,320.26 | 1,311.27 | 1,064.89 | -52.79 |
Other Assets | 219.11 | 184.27 | 168.08 | 174.18 | 150.45 | 110.16 | 120.34 | 99.06 | 70.15 | 468.42 |
Total Assets | 9,618.99 | 14,844.73 | 13,552.65 | 12,246.67 | 11,368.01 | 10,142.61 | 9,805.09 | 9,248.49 | 7,694.44 | 5,705.16 |
Contingent Liabilities | 1,063.3 | 336.69 | 361.31 | 384.2 | 271.21 | 73.51 | 47.1 | 36.88 | 36.89 | 129.37 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 |
Reserves Total | 22,942.4 | 17,849.25 | 16,710.37 | 14,781.29 | 13,198.05 | 11,913.87 | 10,363.22 | 9,408.4 | 7,337.75 | 4,924.92 |
Total Shareholders Funds | 22,970.62 | 17,877.47 | 16,738.59 | 14,809.51 | 13,226.27 | 11,942.09 | 10,391.44 | 9,436.62 | 7,365.97 | 4,952.05 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 |
Unsecured Loans | 707.29 | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,128.37 | 2,961.33 | 2,773.94 | 771.89 | 373.41 |
Total Debt | 707.29 | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,134.48 | 2,981.07 | 2,776.53 | 787.42 | 410.1 |
Other Liabilities | 131.94 | 372.58 | 121.32 | 136.61 | 205.65 | 88.51 | 2.6 | 2.41 | 4.7 | 121.92 |
Total Liabilities | 23,809.85 | 21,471.27 | 20,597.61 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.09 | 5,484.07 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 3,392.75 | 3,183.65 | 3,026.28 | 2,848.56 | 2,595.06 | 2,260.1 | 2,581.75 | 2,368.53 | 2,107.04 | 1,801.98 |
Less : Accumulated Depreciation | 1,636.5 | 1,437.7 | 1,273.95 | 1,126.07 | 983.11 | 846.62 | 882.63 | 772.16 | 669.04 | 571.3 |
Net Block | 1,756.25 | 1,745.95 | 1,752.33 | 1,722.49 | 1,611.95 | 1,413.48 | 1,699.12 | 1,596.37 | 1,438 | 1,230.68 |
Capital Work in Progress | 197.67 | 172.34 | 109.04 | 131.4 | 200.01 | 286.2 | 419.68 | 270.66 | 276.06 | 294.19 |
Investments | 12,964.79 | 10,332.71 | 8,559.39 | 6,989.95 | 4,713.93 | 3,268.75 | 3,212.68 | 1,866.7 | 1,858.43 | 1,659.52 |
Inventories | 1,142.69 | 1,090.21 | 951.66 | 762.39 | 837.5 | 911.21 | 1,111.18 | 1,145.06 | 968 | 736.63 |
Sundry Debtors | 2,484.47 | 2,505.66 | 2,678.32 | 2,488.75 | 1,835.24 | 2,087.13 | 3,828.91 | 3,879.4 | 3,057.66 | 2,440.83 |
Cash and Bank Balance | 129.15 | 93.79 | 29.63 | 15.79 | 88.26 | 256.48 | 177.38 | 252.18 | 74.24 | 48.55 |
Loans and Advances | 925.17 | 696.82 | 743.31 | 1,642.2 | 1,662.89 | 1,886.33 | 757.78 | 674.19 | 528.03 | 371.94 |
Total Current Assets | 4,681.48 | 4,386.48 | 4,402.93 | 4,909.12 | 4,423.89 | 5,141.15 | 5,875.25 | 5,950.83 | 4,627.93 | 3,597.95 |
Current Liabilities | 3,249.79 | 2,952.14 | 2,168.39 | 1,834.31 | 1,827.48 | 1,855.86 | 1,796.56 | 1,727.02 | 1,867.56 | 1,882.99 |
Provisions | 354.74 | 162.52 | 148.49 | 133.11 | 118.45 | 121.75 | 93.2 | 57.97 | 87.37 | 151.38 |
Total Current Liabilities & Provisions | 3,604.54 | 3,114.66 | 2,316.88 | 1,967.41 | 1,945.92 | 1,977.62 | 1,889.76 | 1,784.98 | 1,954.93 | 2,034.37 |
Net Current Assets | 1,076.94 | 1,271.82 | 2,086.05 | 2,941.71 | 2,477.97 | 3,163.54 | 3,985.49 | 4,165.85 | 2,672.99 | 1,563.58 |
Deferred Tax Assets | 475.61 | 1,160.25 | 1,137.47 | 1,118.72 | 1,081.34 | 1,063.23 | 1,056.45 | 820.62 | 589.41 | 24.84 |
Deferred Tax Liability | 309.77 | 213.5 | 214.2 | 265.43 | 276.6 | 351.1 | 395.83 | 226.56 | 188.25 | 157.23 |
Net Deferred Tax | 165.84 | 946.75 | 923.27 | 853.29 | 804.74 | 712.13 | 660.62 | 594.06 | 401.16 | -132.39 |
Other Assets | 7,648.37 | 7,001.7 | 7,167.54 | 6,011.27 | 7,197.08 | 6,320.98 | 3,397.52 | 3,721.92 | 1,511.43 | 868.49 |
Total Assets | 23,809.85 | 21,471.26 | 20,597.62 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.08 | 5,484.07 |
Contingent Liabilities | 2,658.49 | 3,443.3 | 3,325.06 | 3,730.17 | 4,430.59 | 3,680.94 | 4,549.6 | 3,720.76 | 4,594.01 | 5,326.65 |
Cash Flow (Figures in Rs. Crores)
Net Profit before Tax and Extr... | 569.19 |
Depreciation | 630.81 |
Interest (Net) | 500.14 |
P/L on Sales of Assets | -0.83 |
P/L on Sales of Invest | -7.05 |
Prov. and W/O (Net) | 68.38 |
P/L in Forex | -342.59 |
Total Adjustments (PBT and Ext... | 1,009.81 |
Operating Profit before Workin... | 1,579 |
Trade and 0ther Receivables | 969.51 |
Inventories | -513.86 |
Trade Payables | -734.41 |
Total Adjustments (OP before W... | -796.95 |
Cash Generated from/(used in) ... | 782.05 |
Direct Taxes Paid | -1,047.49 |
Total Adjustments(Cash Generat... | -1,047.49 |
Cash Flow before Extraordinary... | -265.44 |
Net Cash from Operating Activi... | -265.44 |
Purchased of Fixed Assets | -898.38 |
Sale of Fixed Assets | 2.08 |
Sale of Investments | 7.05 |
Interest Received | 17.16 |
Cancellation of Investment in ... | 5,449.61 |
Net Cash used in Investing Act... | 4,386.82 |
Proceeds from Issue of shares ... | 1.2 |
Proceed from Short Tem Borrowi... | 481.12 |
Of the Long Tem Borrowings | -3,649.49 |
Of Financial Liabilities | -104.43 |
Dividend Paid | -117.75 |
Interest Paid | -516.78 |
Net Cash used in Financing Act... | -3,906.13 |
Net Profit before Tax and Extr... | 7,000.75 |
Depreciation | 202.16 |
Interest (Net) | 103.58 |
Dividend Received | 228.39 |
P/L on Sales of Assets | 0.25 |
P/L on Sales of Invest | -7.05 |
Prov. and W/O (Net) | 33.39 |
P/L in Forex | -173.41 |
Total Adjustments (PBT and Ext... | -5,884.79 |
Operating Profit before Workin... | 1,115.96 |
Trade and 0ther Receivables | -63.2 |
Inventories | -147.52 |
Trade Payables | -272.03 |
Total Adjustments (OP before W... | -740.31 |
Cash Generated from/(used in) ... | 375.65 |
Direct Taxes Paid | -871.1 |
Total Adjustments(Cash Generat... | -871.1 |
Cash Flow before Extraordinary... | -495.45 |
Net Cash from Operating Activi... | -495.45 |
Purchased of Fixed Assets | -195.11 |
Sale of Fixed Assets | 0.5 |
Sale of Investments | 7.05 |
Interest Received | 278.45 |
Invest.In Subsidiaires | -9.05 |
Loans to Subsidiaires | -2,562.51 |
Cancellation of Investment in ... | 5,449.61 |
Net Cash used in Investing Act... | 3,197.17 |
Proceeds from Issue of shares ... | 1.2 |
Proceed from Short Tem Borrowi... | 150 |
Of the Long Tem Borrowings | -2,449.18 |
Of Financial Liabilities | -35.63 |
Dividend Paid | -70.45 |
Interest Paid | -262.39 |
Net Cash used in Financing Act... | -2,666.45 |
Company Details
Registered Office |
|
Address | B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Registrars |
|
Address | B/2 Mahalaxmi Chambers |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Management |
|
Name | Designation |
Glenn Saldanha | Chairman & Managing Director |
Cheryl Pinto | Executive Director (Corporate) |
V S Mani | Executive Director & Group CFO |
B E Saldanha | Non Executive Director |
Rajesh Desai. | Independent Non Exe. Director |
Sona Saira Ramasastry | Independent Non Exe. Director |
Dipankar Bhattacharjee | Independent Non Exe. Director |
V R Iyer | Independent Non Exe. Director |